<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02094066</url>
  </required_header>
  <id_info>
    <org_study_id>2012/683</org_study_id>
    <nct_id>NCT02094066</nct_id>
  </id_info>
  <brief_title>The Effect of Tranexamic Acid for Total Hip Arthroplasty</brief_title>
  <official_title>The Effects of High Doze Tranexamic Acid Application on Hemorrhage, Blood Transfusion, Fibrin Degradation Products, and Kidney Functions for Total Hip Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TC Erciyes University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TC Erciyes University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the effects of tranexamic acid on hemorrhage, blood
      transfusion, fibrin degradation products and kidney functions for total hip arthroplasty.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Orthopedic surgery may be associated with substantial blood loss requiring transfusion of
      erythrocytes.Transfusion of allogeneic erythrocytes is not free of adverse events and has
      been associated with transmission of infectious diseases, increased postoperative bacterial
      infection, immune sensitization, and transfusion related acute lung injury. Measures taken to
      allay concerns about the safety of blood transfusions have translated into the increasing
      cost of allogeneic blood units. Blood banks regularly undergo blood shortages. For these
      reasons, there is a need to reduce allogeneic blood transfusions. A number of effective
      interventions have been developed, such as preoperative autologous donation, cell salvage, or
      the use of erythropoietin. Pharmacologic agents such as aprotinin, tranexamic acid, or
      epsilon-aminocaproic acid (EACA) could reduce perioperative blood loss by interfering with
      fibrinolysis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hemorrhage</measure>
    <time_frame>intraoperative</time_frame>
    <description>the amount of bleeding in aspirator and sponges</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>erythrocyte transfusion</measure>
    <time_frame>intraoperative and postoperative 3 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>tranexamic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>serum physiologic</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>preoperative 100 cc serum physiologic</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tranexamic acid</intervention_name>
    <description>preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes</description>
    <arm_group_label>tranexamic acid</arm_group_label>
    <other_name>lysteda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>serum physiologic</intervention_name>
    <description>preoperative 100 cc ıv serum physiologic</description>
    <arm_group_label>serum physiologic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA 2-3

          -  18-75 age

          -  total hip arthroplasty surgery

          -  regional anesthesia

        Exclusion Criteria:

          -  allergies to drug

          -  liver and kidney failure

          -  ischemic heart disease

          -  coagulopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>seher orbay yasli, resident</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erciyes university medicine faculty</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>seher orbay yasli, resident</last_name>
    <phone>+905052401933</phone>
    <email>sehersin81@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>zeynep tosun, prof</last_name>
    <phone>+905326640648</phone>
    <email>zeynep@erciyes.edu.tr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Erciyes univercity medicine faculty</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>seher orbay yasli, resident</last_name>
      <phone>+905052401933</phone>
      <email>sehersin81@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>zeynep tosun, prof</last_name>
      <phone>+905326640648</phone>
      <email>zeynep@erciyes.edu.tr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2014</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2014</study_first_posted>
  <last_update_submitted>March 24, 2014</last_update_submitted>
  <last_update_submitted_qc>March 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>TC Erciyes University</investigator_affiliation>
    <investigator_full_name>seher orbay yasli</investigator_full_name>
    <investigator_title>resident</investigator_title>
  </responsible_party>
  <keyword>tranexamic acid</keyword>
  <keyword>total hip arthroplasty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

